Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question?' Expert opinion on pharmacotherapy [Expert Opin Pharmacother] Journal article | | Title | Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question?' | | Author(s) | Toyoda H, Kumada T | | Institution | Ogaki Municipal Hospital, Department of Gastroenterology, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan +81 584 81 3341 ; +81 584 75 5715 ; tkumada@he.mirai.ne.jp. | | Source | Expert Opin Pharmacother 2009 Nov 6. | | Abstract | Background: There has been no direct comparison of the antiviral efficacy and the adverse effects of peginterferon (PEG-IFN) alfa-2a and PEG-IFN alfa-2b when used in combination therapy with ribavirin for chronic hepatitis C virus (HCV) infection.
Objective: A head-to-head comparison of the antiviral efficacy and the adverse effects of PEG-IFN alfa-2a and PEG-IFN alfa-2b was made based on the results from the IDEAL trial, a large, multicenter, prospective, randomized, controlled study performed in the United States to provide guidance for the selection of the right PEG-IFN in clinical settings.
Methods: The results of the IDEAL trial were analyzed. Results/conclusion: The antiviral efficacy, as well as the adverse effects, of PEG-IFN alfa-2a and PEG-IFN alfa-2b are similar in US patients with HCV genotype 1 when used in a standard dosing regimen in combination with ribavirin. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19891593 |
|
|
| |
Advertise on this site.
| | |
|
